1. Home
  2. PAAS vs BIIB Comparison

PAAS vs BIIB Comparison

Compare PAAS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pan American Silver Corp.

PAAS

Pan American Silver Corp.

HOLD

Current Price

$58.83

Market Cap

24.3B

Sector

N/A

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$183.97

Market Cap

27.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAAS
BIIB
Founded
1994
1978
Country
Canada
United States
Employees
9348
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3B
27.1B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
PAAS
BIIB
Price
$58.83
$183.97
Analyst Decision
Buy
Buy
Analyst Count
4
27
Target Price
$57.75
$199.46
AVG Volume (30 Days)
5.0M
1.1M
Earning Date
05-05-2026
04-29-2026
Dividend Yield
0.91%
N/A
EPS Growth
N/A
N/A
EPS
N/A
8.79
Revenue
N/A
$9,890,600,000.00
Revenue This Year
$36.06
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$33.54
$20.16
Revenue Growth
N/A
2.22
52 Week Low
$22.69
$115.28
52 Week High
$69.99
$202.41

Technical Indicators

Market Signals
Indicator
PAAS
BIIB
Relative Strength Index (RSI) 57.39 52.91
Support Level $52.84 $181.24
Resistance Level $59.90 $188.76
Average True Range (ATR) 2.01 5.64
MACD 0.61 0.39
Stochastic Oscillator 78.98 85.12

Price Performance

Historical Comparison
PAAS
BIIB

About PAAS Pan American Silver Corp.

Pan American Silver Corp is a mining company principally engaged in the operation and development of, and exploration for, silver and gold-producing properties and assets. The company's principal products are silver and gold, although it also produces and sells zinc, lead, and copper. Its operating mines comprise La Colorada, Dolores, Huaron, Morococha, Shahuindo, La Arena, Timmins West, Bell Creek, Manantial Espejo, and San Vicente mines.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: